Showing results (31-40 of 100) with videos related to

Sort By:
Pageof 10
The International Journal of Neuropsychopharmacology|March 2, 2005
Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patientsRobert C Smith, Jean-Pierre Lindenmayer, Nigel Bark, et al.
Journal of Psychiatric Practice|May 21, 2010
Assessment of clinician awareness of nonadherence using a new structured rating scaleCarol D Clayton, Jeffrey Veach, Wayne Macfadden, et al.
Psychiatric Rehabilitation Journal|April 4, 2017
Predictors of response to cognitive remediation in service recipients with severe mental illnessJean-Pierre Lindenmayer, Veronica Anna Ozog, Anzalee Khan, et al.
Clinical Schizophrenia & Related Psychoses|December 21, 2011
Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophreniaJean Pierre Lindenmayer, Frank Tedeschi, Anna Yusim, et al.
Schizophrenia Research|August 11, 2015
COMT genotype and response to cognitive remediation in schizophreniaJean-Pierre Lindenmayer, Anzalee Khan, Herbert Lachman, et al.
Journal of Managed Care & Specialty Pharmacy|October 27, 2016
Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with SchizophreniaJoanna P MacEwan, Felicia M Forma, Jason Shafrin, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|June 2, 2009
Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophreniaDavid Hough, Jean-Pierre Lindenmayer, Srihari Gopal, et al.
Neuropsychiatric Disease and Treatment|August 5, 2022
Healthcare Provider Engagement with a Novel Dashboard for Tracking Medication Ingestion: Impact on Treatment Decisions and Clinical Assessments for Adults with SchizophreniaJeffrey M Cochran, Hui Fang, John G Sonnenberg, et al.
The Journal of Clinical Psychiatry|May 5, 2015
Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month studyLarry Alphs, Carmela Benson, Kimberly Cheshire-Kinney, et al.
Patient Preference and Adherence|August 4, 2022
Participant Engagement and Symptom Improvement: Aripiprazole Tablets with Sensor for the Treatment of SchizophreniaJeffrey M Cochran, Hui Fang, Christophe Le Gallo, et al.
Pageof 10